March 01, 2026 — 4 articles reviewed
This cycle’s coverage spans a wide clinical arc, from professional athletes rethinking opioid reliance to mounting epidemiological evidence linking chronic cannabis use with psychiatric and gastrointestinal harm. The throughline is clear: cannabis medicine is maturing, and with that maturity comes a sharper obligation to weigh both benefit and risk with genuine precision.
💊 Cannabis as an Opioid Alternative in High-Impact Pain Management
NFL players and other professional athletes are publicly reconsidering traditional opioid painkillers in favor of cannabinoid-based approaches, reflecting a broader clinical conversation about multimodal analgesia. The risk-benefit calculus is shifting as evidence accumulates that THC and CBD may offer meaningful musculoskeletal pain relief without the addiction liability and overdose risk inherent to chronic opioid use. For clinicians, this trend reinforces the importance of discussing cannabinoid options with patients managing repetitive injury and chronic pain, particularly those with opioid exposure history. The research base remains incomplete, however, and long-term outcomes data in physically demanding populations are still needed before broad clinical endorsement.
- #45Why Steelers And Other NFL Players Are Reconsidering Traditional Painkillers
🏛️ Regulatory Growing Pains and the Evolving Cannabis Marketplace
New York’s cannabis landscape at the five-year mark illustrates the friction between medical intent and market reality that clinicians encounter nationwide. Incomplete regulatory rollouts, shifting product availability, and the emergence of novel delivery formats like THC and CBD beverages all affect how patients access and use cannabis therapeutically. Physicians should recognize that the market environment directly shapes patient behavior, from product selection to dosing consistency. Staying informed on state-level regulatory developments is not optional; it is part of responsible prescribing and counseling in cannabis medicine.
- #72New York Cannabis, Five Years In: Markets, Medicine, and the Messy Middle
🧠 Cannabis, Anxiety, and Depression: A Strengthening Signal
Epidemiological evidence linking regular cannabis use with worsening anxiety and depression continues to strengthen over time, challenging the widespread patient belief that cannabis is a uniformly safe anxiolytic. The clinical implication is straightforward: routine screening for cannabis use should carry the same rigor as alcohol screening, especially in adolescents and young adults with neurodevelopmental vulnerability. Frequency, dose, cannabinoid profile, and chronicity all modulate risk, meaning blanket reassurance or blanket alarm are equally unhelpful. Clinicians should use this evidence to anchor individualized risk-benefit conversations and to monitor mood trajectories in active cannabis users.
- #75Link between cannabis and anxiety, depression has ‘strengthened over time’ – NY Post
🤢 Cannabis Hyperemesis Syndrome: Rising Prevalence Demands Clinical Vigilance
Cannabis hyperemesis syndrome continues its upward trajectory, with 2025 data documenting 4.4 cases per 100,000 emergency department visits, a figure expected to climb alongside expanding legalization and increasing product potency. CHS presents with cyclic severe nausea, vomiting, and abdominal pain that mimics other acute GI emergencies, often leading to costly and unnecessary diagnostic workups when cannabis use is not disclosed or explored. Standard antiemetics are frequently ineffective, and the hallmark of compulsive hot bathing should raise immediate clinical suspicion. Complete cannabis cessation remains the definitive treatment, and early recognition paired with direct patient counseling about this syndrome is the most effective intervention clinicians can offer.
- #78Cannabis Hyperemesis Syndrome: Clinical Signs to Watch
This batch of news captures the duality every cannabis clinician lives with daily: real therapeutic promise on one side, real clinical risk on the other, and the quality of care defined entirely by how honestly and carefully we navigate between them.